Intellia Therapeutics (NTLA) Tops Q1 EPS by 10c
Tweet
Share
E-mail
Get Alerts NTLA Hot Sheet
Join SI Premium – FREE
Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.81), $0.10 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $15.04 million versus the consensus estimate of $13.51 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Alloy (ALOY) files mixed shelf
- Comcast may build data centers, NBCUniversal may enter video game business - Reuters
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
